Pancreatic Cancer Research

ResearcherNational Hospital Organization Kyushu Cancer CenterActive in the last 2 years

Kenji Mitsugi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5019169752, A5108591661. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 18)
Trials
0
Grants
0
Labs led
1
Collaborators
27
Papers, trials and grants by year

2021: 3 papers · 2022: 2 papers · 2023: 6 papers · 2024: 4 papers · 2025: 6 papers · 2026: 5 papers

Papers 26

  1. Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folini… Last author DOI 10.1002/ijc.70072↗
  2. Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 St… Last author DOI 10.1111/ajco.70041↗
  3. Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluor… Last author DOI 10.1177/17588359261442386↗
  4. Effect of biliary drainage and biliary tract infection in unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic ac… Last author DOI 10.1186/s12885-026-16237-2↗
  5. Dynamic analysis of C-reactive protein/albumin ratio in pancreatic cancer Last author DOI 10.21203/rs.3.rs-8417823/v1↗
  6. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NA… Last author DOI 10.1016/j.esmogo.2025.100150↗
  7. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studie… Last author DOI 10.1159/000542137↗
  8. Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from … Last author DOI 10.1177/17588359251320768↗
  9. Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of dat… Last author DOI 10.1177/17588359251393156↗
  10. Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results f… Last author DOI 10.1186/s12885-025-14992-2↗
  11. Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pa… Last author DOI 10.3389/fonc.2025.1626689↗
  12. Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or ge… Co-author DOI 10.1038/s41598-024-55673-7↗
  13. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreat… Last author DOI 10.1038/s41598-024-63172-y↗
  14. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/… Last author DOI 10.1038/s41598-024-65689-8↗
  15. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservat… Last author DOI 10.21203/rs.3.rs-3985196/v1↗
  16. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. Last author DOI 10.1007/s10147-023-02354-6↗
  17. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-… Co-author DOI 10.1038/s41598-023-34962-7↗
  18. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-023-46924-0↗
  19. Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. Last author DOI 10.1159/000527176↗
  20. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observati… Last author DOI 10.21203/rs.3.rs-3677172/v1↗
  21. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel. Co-author DOI 10.21873/anticanres.16335↗
  22. Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAP… Last author DOI 10.1016/j.jgo.2021.06.011↗
  23. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multi… Co-author DOI 10.1186/s12885-021-09139-y↗
  24. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results fr… Co-author DOI 10.1007/s10147-021-01859-2↗
  25. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study). Co-author DOI 10.1097/mpa.0000000000001859↗
  26. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection. Co-author DOI 10.21873/anticanres.15145↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junichi Nakazawa · 25 shared papers, 2021–2026 · strength 3.76
  2. Shiho Arima · 25 shared papers, 2021–2026 · strength 3.76
  3. Futa Koga · 25 shared papers, 2021–2026 · strength 3.76
  4. Mototsugu Shimokawa · 25 shared papers, 2021–2026 · strength 3.76
  5. Taiga Otsuka · 25 shared papers, 2021–2026 · strength 3.76
  6. Tsuyoshi Shirakawa · 25 shared papers, 2021–2026 · strength 3.76
  7. Hiroki Taguchi · 25 shared papers, 2021–2026 · strength 3.76
  8. Taro Shibuki · 21 shared papers, 2021–2026 · strength 2.96
  9. Azusa Komori · 21 shared papers, 2021–2026 · strength 2.96
  10. Yasunori Kawaguchi · 16 shared papers, 2021–2026 · strength 2.60
  11. Yasushi Ide · 17 shared papers, 2021–2026 · strength 2.48
  12. Kazuo Nishikawa · 14 shared papers, 2023–2026 · strength 2.38
  13. Shuji Arita · 14 shared papers, 2023–2026 · strength 2.38
  14. Masaru Fukahori · 14 shared papers, 2021–2025 · strength 1.85
  15. Keisuke Miwa · 11 shared papers, 2023–2026 · strength 1.72
  16. Norio Ureshino · 13 shared papers, 2021–2025 · strength 1.68
  17. Akio Ido · 7 shared papers, 2021–2026 · strength 0.93
  18. Yoshinobu Okabe · 7 shared papers, 2021–2024 · strength 0.91
  19. Tomonori Araki · 4 shared papers, 2025–2026 · strength 0.73
  20. Tomoko Kodama · 3 shared papers, 2023–2024 · strength 0.40
  21. Eishi Baba · 2 shared papers, 2023–2024 · strength 0.30
  22. Atsuko Kakihara · 1 shared paper, 2026 · strength 0.20
  23. Wataru Yoshioka · 1 shared paper, 2026 · strength 0.20
  24. Akiko Todaka · 1 shared paper, 2025 · strength 0.17
  25. Tomomi Koike · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.